Cambridge Healthtech Institute’s 3rd Annual

Emerging Immuno-Oncology Targets and Modalities

Next-Generation Targets and Modalities for Cancer Immunotherapy and Combinations

June 19-20, 2019  


While cancer immunotherapy has made a giant leap in the past five years, the majority of therapies at advanced stages of development are clustered in a similar target space. The increased investment in immuno-oncology has created an urgent opportunity to discover and populate new target spaces and develop new modalities that either present new classes of immunotherapies or can be used in combination with existing products. Cambridge Healthtech Institute’s 3rd Annual Emerging Immuno-Oncology Targets and Modalities conference will cover the emerging target space, including immunomodulatory inhibitor and agonist targets, stromal and immune cell targets, and strategies for rational combination immunotherapy. Emerging modalities, including adoptive T cell therapy, oncolytic virus immunotherapy, personalized cancer vaccines, and next-gen engineered protein constructs will be discussed. Case studies of preclinical and translational approaches to the discovery and validation of new immuno-oncology targets and combinations will be presented.

EMERGING CHECKPOINT TARGETS FOR IMMUNOMODULATORY ANTIBODIES

TIM3 Antibody for Immunotherapy

Xiaomo Jiang, PhD, Investigator, Immuno-Oncology, Novartis Institutes for BioMedical Research

Reverse Translational Biomarker Analysis in Development of an ICOS Agonist

Elizabeth Trehu, MD, CMO, Jounce Therapeutics

TARGETING INNATE IMMUNITY AND TUMOR MICROENVIRONMENT

Microenvironmental Links between Adipose Tissue and Cancer

Daniela Cipolletta, PhD, Lab Head, Investigator III, Immuno-Oncology, Novartis Institutes for BioMedical Research

EMERGING MODALITIES FOR IMMUNOTHERAPY OR COMBINATIONS

PD-1 Antibody Is Foundational Anti-Cancer Therapy Both as Single Agent and with Additional Modalities

Roy Baynes, MD, PhD, Senior Vice President and Head, Global Clinical Development, CMO, Merck Research Laboratories

Talk Title to be Announced

Sema Kurtulus, PhD, Investigator II, Translational 


For more details on the conference, please contact:
Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
Email: juliab@healthtech.com

For partnering and sponsorship information, please contact:

Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286
Email: reymael@healthtech.com

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: jvacca@healthtech.com